文献速递膀胱癌与上尿路尿路上皮癌

社会脆弱性与接受根治性膀胱切除术的膀胱癌患者接受新辅助化疗的关系

Social Vulnerability and Receipt of Neoadjuvant Chemotherapy in Patients Undergoing Radical Cystectomy for Bladder Cancer.
PubMed 文献 · Urology · 2024-05-18

研究纳入2000至2022年在本机构接受根治性膀胱切除术的非转移性肌层浸润性膀胱癌患者978例,按居住地邮编分配CDC社会脆弱性指数(SVI)五分位。最脆弱组接受新辅助化疗的比值比低于最不脆弱组(OR 0.61,0.39-0.95),社会经济地位和家庭构成/残疾亚主题亦呈相似关联。作者认为社会脆弱性与新辅助化疗利用不足和差异相关。

要点

  • 978例中490例(50.1%)接受了新辅助化疗。
  • 最脆弱组较最不脆弱组接受新辅助化疗的OR为0.61(0.39-0.95)。
  • 社会经济地位亚主题OR 0.56(0.36-0.86),家庭构成/残疾亚主题OR 0.57(0.33-0.99)。

核心结论

  • 不良健康社会决定因素即社会脆弱性,与接受根治性膀胱切除术的肌层浸润性膀胱癌患者新辅助化疗利用不足和差异相关。
  • 作者认为识别脆弱人群的策略可能有助于实现更有针对性的干预,从而改善膀胱癌诊疗的公平性。

研究设计与样本

  • 研究查询本机构数据库,纳入2000至2022年接受根治性膀胱切除术的非转移性肌层浸润性膀胱癌患者。
  • 通过居住地邮编分配社会脆弱性指数(SVI),并按SVI五分位分组(从最不脆弱到最脆弱)。
  • 采用多变量logistic回归评估SVI与新辅助化疗接受情况的关系,调整年龄、种族、性别和癌症分期。
  • 进行亚组分析评估SVI各亚主题(社会经济地位、家庭构成/残疾、种族/民族/语言、住房/交通)与新辅助化疗接受情况的关系。

主要发现

  • 共识别978例患者,其中490例(50.1%)接受了新辅助化疗。
  • 接受新辅助化疗的患者SVI较低、较年轻且分期>cT2(均P<.05)。
  • 最脆弱患者较最不脆弱患者接受新辅助化疗的OR为0.61(0.39-0.95)。
  • SVI亚主题分析显示社会经济地位(OR 0.56,0.36-0.86)和家庭构成/残疾(OR 0.57,0.33-0.99)呈相似关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the association between a population-level measure of social determinants of health, the Centers for Disease Control and Prevention Social Vulnerability Index (SVI), and receipt of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy. METHODS: We queried our institutional database for patients with nonmetastatic MIBC treated with radical cystectomy between 2000 and 2022. Patients were assigned an SVI via ZIP code of residence and grouped into quintiles of SVI (ie, least vulnerable to most vulnerable). Multivariable logistic regression was performed to evaluate the association between SVI and receipt of neoadjuvant chemotherapy, adjusting for age, race, gender, and cancer stage. A sub-analysis was performed to evaluate the association between subthemes of SVI (socioeconomic status, household composition/disability, race/ethnicity/language, and housing/transportation) and receipt of neoadjuvant chemotherapy. RESULTS: Of the 978 patients identified, 490 (50.1%) received neoadjuvant chemotherapy. Patients that received neoadjuvant chemotherapy had a lower SVI, were younger, and had >cT2 stage (all, P <.05). The most vulnerable patients had lower odds of receiving neoadjuvant chemotherapy (OR 0.61, 0.39-0.95) compared to the least vulnerable patients. Analysis of subthemes of SVI demonstrated similar associations by socioeconomic status (OR 0.56, 0.36-0.86) and household composition/disability (OR 0.57, 0.33-0.99). CONCLUSION: Adverse social determinants of health, or social vulnerability, are associated with suboptimal and disparate utilization of neoadjuvant chemotherapy in patients with MIBC undergoing radical cystectomy. Strategies for identifying vulnerable populations may allow for more targeted interventions that would improve equity in bladder cancer care.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Sekar RR, Irani S, Maganty A, et al. Social Vulnerability and Receipt of Neoadjuvant Chemotherapy in Patients Undergoing Radical Cystectomy for Bladder Cancer. Urology. 2024. PMID: 38763474. doi:10.1016/j.urology.2024.05.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。